<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20101">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02024711</url>
  </required_header>
  <id_info>
    <org_study_id>EYE-C-7.00</org_study_id>
    <nct_id>NCT02024711</nct_id>
  </id_info>
  <brief_title>EYEFILL® C. -US Viscoelastic Clinical Investigation</brief_title>
  <official_title>EYEFILL® C.-US Viscoelastic Clinical Investigational Protocol- For Institutional Review Boards / Ethical Review Committees and Clinical Investigators</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Croma Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Croma Pharmaceuticals Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this multicenter, prospective, randomized clinical study is to determine the
      safety and effectiveness of the EYEFILL® C.-US Viscoelastic in patients undergoing cataract
      extraction and intraocular lens (IOL) implantation surgery.

      EYEFILL® C.-US Viscoelastic is designed to create and maintain space, to protect the corneal
      endothelium and other intraocular tissues, and to manipulate tissues during surgery.

      EYEFILL® C.-US Viscoelastic may also be used to coat intraocular lenses and instruments
      during cataract extraction and intraocular lens insertion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Preservation of Endothelium</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Specular Microscope Photographs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of IOP spikes &gt;/= 30 mmHg at all postoperative follow-up visits</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Tonometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative rate and severity of inflammatory response at all postoperative follow-up visits</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Anterior Chamber Flare and Cell Assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative rate and severity of other device-related adverse events at all postoperative follow-up visits</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Clinical Assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">284</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>EYEFILL® C.-US Viscoelastic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EYEFILL ® C.-US is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healon® Viscoelastic (CONTROL)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healon® is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EYEFILL® C.-US Viscoelastic</intervention_name>
    <description>A comparison between EYEFILL ® C.-US and Healon® Viscoelastic (CONTROL) for the identical use during cataract extraction.</description>
    <arm_group_label>EYEFILL® C.-US Viscoelastic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Healon® Viscoelastic (CONTROL)</intervention_name>
    <arm_group_label>Healon® Viscoelastic (CONTROL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any race

          -  Older than 21 years

          -  Cataract requiring cataract extraction in at least 1 eye

          -  Clear intraocular media other than cataract

          -  Able to provide written informed consent

          -  Able and willing to comply with required follow-up schedule

          -  Competent to understand the procedure and the actions asked of him/her as a research
             subject

        Exclusion Criteria:

          -  Monocular

          -  Ocular infection

          -  History of glaucoma, Ocular Hypertension (IOP &gt; 21 mmHg) likely to require IOP
             lowering medications, ocular condition requiring IOP lowering medication, condition
             preventing reliable Goldmann applanation tonometry, known steroid responder

          -  Previous intraocular surgery in the operative eye

          -  Previous serious corneal disease or known endothelial cell loss / damage (in
             operative eye)

          -  History of chronic or recurrent inflammatory eye disease (in operative eye)

          -  Evidence of retinal vascular disease (in operative eye)

          -  Uncontrolled diabetes or proliferative diabetic retinopathy

          -  Acute or chronic disease or illness that would increase the operative risk

          -  Allergy to anesthetics or other postoperative medications

          -  Known hypersensitivity to sodium hyaluronate or other components in viscoelastic

          -  Patient in any other clinical trial within the 30 days prior to the start of the
             study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald R Sanders, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Center for Clinical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monica L Sanders, MS</last_name>
    <phone>630-530-9700</phone>
    <phone_ext>112</phone_ext>
    <email>monica@drsmd.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kimberley Doney, MBA</last_name>
    <phone>781-860-0388</phone>
    <email>kdoney@rcn.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barnet Dulaney Perkins Eye Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patti Crincoli</last_name>
      <phone>602-955-1000</phone>
    </contact>
    <investigator>
      <last_name>Scott A. Perkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shasta Eye Medical Group</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Kelly, COA</last_name>
      <phone>530-223-2500</phone>
    </contact>
    <investigator>
      <last_name>Bruce E. Silverstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Argus Research at Cape Coral Eye Center</name>
      <address>
        <city>Cape Coral</city>
        <state>Florida</state>
        <zip>33904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Frederick, CCRC</last_name>
      <phone>239-443-3760</phone>
      <email>jennifer.frederick@tysoneye.com</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen Bellaire, CCRC</last_name>
      <phone>239-542-2020</phone>
      <phone_ext>2028</phone_ext>
      <email>kathleen.bellaire@tysoneye.com</email>
    </contact_backup>
    <investigator>
      <last_name>Farrell C. Tyson, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eye Centers of Florida</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leigh V. Wilson, COA, COSA</last_name>
      <phone>239-939-3456</phone>
    </contact>
    <investigator>
      <last_name>David C. Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newsom Eye and Laser Center</name>
      <address>
        <city>Sebring</city>
        <state>Florida</state>
        <zip>33870</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leesa R. Skipper, RN, CRNO</last_name>
      <phone>863-385-1544</phone>
    </contact>
    <investigator>
      <last_name>Hunter T. Newsom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Lakes Eye Care</name>
      <address>
        <city>Saint Joseph</city>
        <state>Michigan</state>
        <zip>49085</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marilyn S. Herrman, COA</last_name>
      <phone>269-428-3300</phone>
    </contact>
    <investigator>
      <last_name>David L. Cooke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Silverstein Eye Centers</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Bentley, BS, CRC</last_name>
      <phone>816-358-3600</phone>
    </contact>
    <investigator>
      <last_name>Steven M. Silverstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Eye Care</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet R. Zeitzmann, RN</last_name>
      <phone>636-390-3999</phone>
    </contact>
    <investigator>
      <last_name>Michael S. Korenfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Davis Duehr Dean Medical Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>December 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cataract</keyword>
  <keyword>Intraocular Lens</keyword>
  <keyword>IOL</keyword>
  <keyword>Aphakia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
